Jinsy A Andrews Selected Research

reldesemtiv

1/2023	COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
1/2023	Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
1/2022	Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
7/2021	Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
1/2021	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
1/2021	Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jinsy A Andrews Research Topics

Disease

13	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 07/2023 - 07/2016
5	Disease Progression 01/2023 - 01/2018
2	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 07/2021 - 01/2021
2	Nausea 01/2021 - 01/2019
2	Fatigue 01/2021 - 01/2019
1	Liver Diseases (Liver Disease) 07/2023
1	Diabetic Neuropathies (Diabetic Neuropathy) 07/2023
1	Muscle Cramp (Cramp) 07/2023
1	Renal Insufficiency (Renal Failure) 07/2023
1	Spinal Stenosis (Stenosis, Spinal) 07/2023
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2019
1	Dizziness (Lightheadedness) 01/2019
1	Weight Loss (Weight Reduction) 01/2019
1	Respiratory Insufficiency (Respiratory Failure) 01/2018

Drug/Important Bio-Agent (IBA)

6	reldesemtivIBA 01/2023 - 01/2021
3	TroponinIBA 01/2021 - 01/2018
3	CK-2017357IBA 01/2019 - 07/2016
2	Biomarkers (Surrogate Marker)IBA 12/2022 - 01/2022
2	tofersenIBA 01/2022 - 01/2022
1	shakuyaku-kanzoh-tohIBA 07/2023
1	Superoxide Dismutase-1IBA 01/2022
1	Investigational DrugsIBA 01/2022
1	Antisense OligonucleotidesIBA 01/2022
1	Riluzole FDA LinkGeneric 11/2020
1	Indicators and Reagents (Reagents)IBA 01/2018

Therapy/Procedure

1	Kampo Medicine (Kampo) 07/2023
1	Noninvasive Ventilation 01/2022
1	Therapeutics 01/2022
1	Tracheostomy 01/2018